These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15615155)

  • 1. Stopping statins is bad for your health.
    Sherman FT
    Geriatrics; 2004 Nov; 59(11):8, 10. PubMed ID: 15615155
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical and sociological characteristics of long-term therapy of statins (simvastatin) administration to patients with hyper-cholesterinemia in regular medical settings in Russia].
    Ageev FT; Abramian AA; Belenkov IuN
    Kardiologiia; 2006; 46(5):67. PubMed ID: 16858359
    [No Abstract]   [Full Text] [Related]  

  • 3. Why some patients respond poorly to statins and how this might be remedied.
    Thompson GR; O'Neill F; Seed M
    Eur Heart J; 2002 Feb; 23(3):200-6. PubMed ID: 11792134
    [No Abstract]   [Full Text] [Related]  

  • 4. Is carotid intima-media thickness a reliable clinical predictor?
    Spence JD
    Mayo Clin Proc; 2008 Nov; 83(11):1299-300; author reply 1300-1. PubMed ID: 18990332
    [No Abstract]   [Full Text] [Related]  

  • 5. History of the cholesterol controversy in Britain.
    Thompson GR
    QJM; 2009 Feb; 102(2):81-6. PubMed ID: 19042967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins for all.
    Neild GH
    Transplantation; 2000 May; 69(9):1767-8. PubMed ID: 10830204
    [No Abstract]   [Full Text] [Related]  

  • 7. Over-the-counter statins.
    Malik NN
    Lancet; 2004 Jul 31-Aug 6; 364(9432):411. PubMed ID: 15288726
    [No Abstract]   [Full Text] [Related]  

  • 8. [4S [Scandinavian Simvastatin Survival Study]].
    Koizumi J; Yoshida I
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():410-5. PubMed ID: 11347105
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients: why is someone still using the phase I diet for patients at risk for atherosclerosis?
    Banks T
    Am J Cardiol; 1999 Mar; 83(5):818. PubMed ID: 10080453
    [No Abstract]   [Full Text] [Related]  

  • 10. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
    [No Abstract]   [Full Text] [Related]  

  • 11. Statins for high-risk patients without heart disease or high cholesterol.
    Med Lett Drugs Ther; 2006 Jan; 48(1225):1-3. PubMed ID: 16374400
    [No Abstract]   [Full Text] [Related]  

  • 12. [SBU should investigate what is an evidence-based and cost-effective use of statins].
    Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
    Lakartidningen; 2009 Aug 5-18; 106(32-33):1992-4. PubMed ID: 19764381
    [No Abstract]   [Full Text] [Related]  

  • 13. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on statins.
    Mason P
    J Vasc Nurs; 2004 Jun; 22(2):49-50. PubMed ID: 15179417
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk factor levels, risk factor combinations, and residual coronary risk: population-based estimates for secondary prevention patients using statins.
    Krobot KJ; Wagner A; Siebert U
    Eur J Prev Cardiol; 2012 Feb; 19(1):109-17. PubMed ID: 21450620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of coronary heart disease: statins are even less effective than paper shows.
    Taylor D; Jenkins A; Conradi P
    BMJ; 2004 Feb; 328(7436):404; author reply 405. PubMed ID: 14962885
    [No Abstract]   [Full Text] [Related]  

  • 17. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe.
    Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR
    Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996
    [No Abstract]   [Full Text] [Related]  

  • 18. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Kandzari DE; Goldschmidt-Clermont PJ
    JAMA; 1999 Feb; 281(5):415; author reply 417-9. PubMed ID: 9952193
    [No Abstract]   [Full Text] [Related]  

  • 19. The statins in preventive cardiology.
    Steinberg D
    N Engl J Med; 2008 Oct; 359(14):1426-7. PubMed ID: 18832243
    [No Abstract]   [Full Text] [Related]  

  • 20. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Atheroscler Suppl; 2004 Oct; 5(3):115-23. PubMed ID: 15531284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.